HighCape Capital
Overview
HighCape Capital is a growth equity fund created in 2013 by a group of highly experienced executives for the sole purpose of helping innovative Life Sciences companies transition from the initial stages of their business cycle into successful, thriving organizations . The firm prefers to invest in commercial-stage life sciences companies .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Cybrexa Therapeutics | Mar 2021 | Series B | - |
| Alphina Therapeutics | Sep 2021 | Series A | Co-investor |
| Wellinks | Nov 2021 | Series C | - |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is HighCape Capital based?
Headquarters information for HighCape Capital is not publicly available.
When was HighCape Capital founded?
HighCape Capital was founded in 2013.
How many portfolio companies does HighCape Capital have?
HighCape Capital has 4 portfolio companies in Caplight's dataset.
What are some companies in HighCape Capital's portfolio?
Portfolio companies visible on Caplight include Cybrexa Therapeutics, Alphina Therapeutics, Wellinks.
What was HighCape Capital's most recent investment shown here?
HighCape Capital's most recent investment in this portfolio sample was in Wellinks in 2021.
What sectors does HighCape Capital focus on?
HighCape Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software.
What company stages does HighCape Capital focus on?
HighCape Capital typically invests at the Mid stage.
What is HighCape Capital's AUM?
HighCape Capital's assets under management are estimated between $100.0M and $250.0M.